Hospital Universitario Vall d'Hebron

Barcelona, Catalonia 8035

1 studies enrolling now · 8 studies all time

What they study most

Advanced Breast Cancer, Advanced Lung Cancer, HER2 Mutation-Related Tumors, HER2-positive Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Endometrial Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Metastatic Breast Cancer, HER2-positive Solid Tumors, HR-positive, HER2-negative Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer

Studies at this site

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — Recruiting now
• A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies — Running, not enrolling
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors — Stopped early
• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse — Stopped early
• Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) — Completed
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex — Completed
• Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment — Completed
• Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement — Completed